| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10587564 | Bioorganic & Medicinal Chemistry Letters | 2013 | 5 Pages |
Abstract
The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Pauline C. Ting, Joe F. Lee, Rongze Kuang, Jianhua Cao, Danlin Gu, Ying Huang, Zhidan Liu, Robert G. Aslanian, Kung-I. Feng, Daniel Prelusky, James Lamca, Aileen House, Jonathan E. Phillips, Peng Wang, Ping Wu, Daniel Lundell, Richard W. Chapman,